BioSpace News Archive

ANGLE plc a world-leading liquid biopsy company, announces that following a formal tender process, it has appointed PricewaterhouseCoopers LLP as its auditor for the Company and its subsidiaries for the financial year ended 31 December 2020.

Collaboration combines Sosei Heptares’ leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled and medicinal chemistry technologies

FDA publication demonstrates advantages of PhysioMimix in drug safety and metabolism applications, over standard techniques

Enables Itamar to leverage Spry’s existing FDA-cleared technology to bring to market the first device for continuous remote patient monitoring (RPM) of sleep apnea Adds the capability to monitor the longer-term accumulated disease burden of sleep apnea to complement the single night diagnostics commonly used today, including the Company’s existing WatchPAT™ device Paves the way for an end-to-end digital care pathway that can further expand Itamar’s presence in obstructive sleep apnea (OSA)

Accelerate Diagnostics, Inc. announced preliminary financial results for the fourth quarter and full year ending December 31, 2020.

Effective January 4, 2021, North American Partners in Anesthesia will deliver anesthesia services to the Piedmont Orthopedics | OrthoAtlanta ambulatory surgery center in Fayetteville, Georgia.

PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vedanta Biosciences, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million investment in Vedanta, as part of the Pfizer Breakthrough Growth Initiative.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the first patients have been enrolled in its Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with neovascular age-related macular degeneration (wet AMD). Clinical sites, all based in the Uni

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has granted in accordance with the Company’s stock option plan an aggregate of 700,000 options to purchase common shares of the Company to a consultant and a director of the Company. The options granted are exercisable at $0.28 for a period o

Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced new data demonstrating both durable and consistent lowering of blood low-density lipoprotein cholesterol (LDL-C) levels at six months after a single gene editing treatment in non-human primates